Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Importance of Type 2 Inflammation in Adults With Cystic Fibrosis and Recurrent Pulmonary Exacerbations

NCT07892443 is registered in ClinicalTrials.gov with University of Virginia as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07892443 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
Importance of Type 2 Inflammation in Adults With Cystic Fibrosis and Recurrent Pulmonary Exacerbations
Lead sponsor
University of Virginia
Phase
Observational
Overall status
Not yet recruiting
Start date
November 1, 2026
Completion date
May 31, 2031
Enrollment
100 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

cystic fibrosis (cf), type 2 inflammatory disorders

Primary endpoints

Registered primary outcome measures; 1 primary.

  • Baseline Stable-State Absolute Peripheral Blood Eosinophil Count Baseline

    Absolute peripheral blood eosinophil count measured during clinical stability at baseline. Eosinophil counts will be compared between participants who, after 36 months of prospective observation, are classified as having modulator-refractory CF (average of ≥2 qualifying pulmonary exacerbations per year) or modulator-responsive CF (average of \<2 qualifying pulmonary exacerbations per year).

Papers

PubMed papers this trial cites; 1 paper, results papers first, then newest first.

Source: PubMed, NCBI/NLM (public domain).

Lead sponsor's other trials

University of Virginia, most recent start first.

Similar trials

Same condition (Cystic Fibrosis) and phase, most recent start first.